he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看也就是说地址
上一页:癫痫新生儿死亡简析
下一页:哪些抗菌药物可诱发高血压?
- 2022-05-02小儿失神性病症的诊断后怎么办
- 2022-04-272013年国际抗癫痫联合会抗癫痫解毒使用指南
- 2021-11-16癫痫病治疗分析方法都有哪些
- 2021-11-05成都最佳癫痫病治疗分析方法是什么
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 预测癫痫患者再入院风险
- 答疑┃什么样的月经是健康正常的?这几项你达标了吗?
- 病例学习:伴皮层下囊肿的巨脑性脑白质病
- 癫痫治疗障碍仍难以克服
- 抗癫痫药物预防新发癫痫:任重而道远
- FDA批准Aptiom用于治疗患者癫痫发作
- 最新研究 | 转移性乳腺癌一线化疗预后监测新突破
- 手术学习:颅内脊索瘤内镜下三脑室入路治疗
- 儿童癫痫的常见病因是什么?
- 泡温泉时不能忽视的事情
- 祝贺!谢立平教授当选国际泌尿外科学会(SIU)候任主席
- 【预约直播】铿锵的论道 不炎,越来越多--「郁金香论坛」学术沙龙即将举行
- 如何最有效地去除黑头?
- spa中国有五个专业spa会所介绍
- 月经性癫痫患者妊娠期癫痫控制更好
- UCB的Vimpat癫痫新适应症在美国获批
- 男子做男科体检被层层涨价,医生用语带吓唬:不治老婆就跑了
- 癫痫猝死:凶手是谁?
- AP&T:使用anti-TNFα治疗自身免疫性疾病的患者会增加患炎症性肠病的几率
- 睡觉时突然抽搐 新生儿睡觉抽搐怎么办?
- Diabetes Obes Metab:恩格列净对肝脂肪变性和纤维化标志物的影响及其与心肾结局的关系
- 淋病能治好吗? 淋病怎么办?
- 【用药情报站】临床应用应听取各种药种药物禁忌证?
- 癫痫的治疗方法 中医拔罐治疗癫痫的小方法(2)
- 每个女人都是江湖……
- 经期要注意 有些药物蔬果不可食
- FDA对怀孕期间使用丙戊酸钠类药物发送到警告
- 天麻的好处 天麻这些身手你都知道吗
- 不足之处癫痫的先兆研究
- 暴涨981.89%大品种,知名药企过并称
- 女性癫痫遗传吗 癫痫病人怎样后生健康宝宝
- 戴只腕表就能测癫痫?智能穿戴设备太牛了
- 20130821山东凤凰卫视养生:许新升讲癫痫的危害
- 头皮脑电图或功能核磁共振成像对局灶性癫痫有定位作用
- 近十年熬夜、沉迷网游竟会诱发癫痫?这些不良习惯真的要改改了
- 睡觉时突然抽搐一下 患儿睡觉抽搐怎么办
- 2015 大脑疾病诊疗进展大盘点
- 癫痫患者停药难题有解了?最新分析表明出炉!